🏥 Health & Medicine
Ginkgo set out to industrialize biology — to 'program' cells the way engineers write software, on automated robotic foundries. It's a captivating vision. The reality so far is harder: revenue is shrinking, losses are large (though shrinking after deep cost cuts), and the company is still proving the platform can be a real business. A bet on a future, made cautiously.
Updated · Q1 2026 · March 2026
$150M / yr revenue · public since 2021
↻ The read keeps updating
You're reading the 6 opening chapters. After that, every time Ginkgo files a new report, the chapters get updated here.